- Country profiles
- Data dashboard
- Satellite Pages
- About us
- WHAT'S NEW
The circumstances and condition of Lesbian, Gay, Bisexual, Transgender, and Intersex (LGBTI+) refugees in Thailand is not well researched, even by stakeholders who work with refugees and LGBTI+ communities. This lack of information makes these communities invisible and hard to understand. As a result, stakeholders may be prone to assume that LGBTI+ refugees do not exist and thus ignore their specific needs and vulnerabilities. This may impact the application of protections and provision of services that are unique to the refugees’ sexual orientation, gender identity and expression, and sex characteristics (SOGIESC).
Presented in six separate booklets, the World Drug Report 2020 provides a wealth of information and analysis to support the international community in implementing operational recommendations on a number of commitments made by Member States, including the recommendations contained in the outcome document of the special session of the General Assembly on the world drug problem, held in 2016.
This brief highlights the impact of COVID-19 on migrants, refugees and displaced people and offers some policy recommendations to ensure their health and well-being are protected in COVID-19 prevention, response and recovery.
This brief highlights the disproportionate impact of COVID-19 on certain groups of people and offers some key policy recommendations to ensure no one is left behind in COVID-19 prevention, response and recovery.
This brief highlights the challenges and opportunities for effective risk messaging. Special emphasis is placed on reaching and helping to protect vulnerable communities and deploying tactics to counter misinformation and disinformation which threaten the public health responses and increase societal tensions.
This brief covers key human rights issues that have been long-standing areas of concern in the region and that have been exacerbated by the onset of the COVID-19 crisis. In addition to highlighting the challenges, this brief provides policy advice and recommendations to ensure a rights-based approach is adopted in response to all disasters, including the COVID-19 pandemic.
The objective of this report is to assess the situational landscape during mid-May 2020 surrounding the value chain of the production and distribution of generic antiretroviral medicines in low- and-middle-income countries and to provide recommendations on mitigating the risks of potential disruptions.
The operational handbook provides practical information and tools that complement the recommendations in the guidelines. The strategies described in the operational handbook are based on the latest WHO recommendations which were formulated by Guideline Development Groups using the GRADE approach. In many cases however, the recommendations in their current form lacked sufficient clinical and programmatic detail, which is important for implementation. This operational handbook complements the guidelines with practical advice based on best practices and knowledge from the fields such as pharmacokinetics, pharmacodynamics, microbiology, pharmacovigilance and clinical and programmatic management.
The present WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment includes a comprehensive set of WHO recommendations for the treatment and care of DR-TB. The document includes two new recommendations, one on the composition of shorter regimens and one on the use of the BPaL regimen. In addition, the consolidated guidelines include existing recommendations on treatment regimens for isoniazid-resistant TB and MDR/RR-TB, including longer regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), the use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.